X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (42898) 42898
Dissertation (127) 127
Book Chapter (109) 109
Newspaper Article (92) 92
Magazine Article (44) 44
Conference Proceeding (29) 29
Newsletter (14) 14
Publication (12) 12
Book / eBook (9) 9
Web Resource (5) 5
Book Review (4) 4
Paper (4) 4
Government Document (2) 2
Reference (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (14757) 14757
pyrazoles - pharmacology (13293) 13293
animals (13116) 13116
male (10204) 10204
female (6708) 6708
pyrazole derivatives (6639) 6639
rats (5944) 5944
pyrazoles (5870) 5870
pyrazoles - therapeutic use (5839) 5839
pyrazole (5319) 5319
mice (4760) 4760
pyrazoles - chemistry (4399) 4399
chemistry, organic (4200) 4200
pharmacology & pharmacy (4111) 4111
celecoxib (3690) 3690
pyrazoles - administration & dosage (3163) 3163
middle aged (3133) 3133
derivatives (3121) 3121
chemistry, medicinal (2922) 2922
pyrazoles - chemical synthesis (2881) 2881
dose-response relationship, drug (2855) 2855
chemistry, multidisciplinary (2800) 2800
aged (2754) 2754
adult (2615) 2615
oncology (2554) 2554
pyrazoles - adverse effects (2450) 2450
piperidines - pharmacology (2405) 2405
analysis (2387) 2387
biochemistry & molecular biology (2365) 2365
structure-activity relationship (2256) 2256
cell line, tumor (2129) 2129
chemistry (2057) 2057
ring closure reactions (2008) 2008
molecular structure (1947) 1947
sulfonamides - pharmacology (1870) 1870
pyrimidines - pharmacology (1866) 1866
cancer (1861) 1861
neurosciences (1836) 1836
expression (1806) 1806
rats, sprague-dawley (1783) 1783
inhibitors (1703) 1703
ligands (1702) 1702
treatment outcome (1658) 1658
time factors (1551) 1551
chemistry, inorganic & nuclear (1523) 1523
sulfonamides - therapeutic use (1445) 1445
research (1428) 1428
antineoplastic agents - pharmacology (1405) 1405
activation (1400) 1400
synthesis (1365) 1365
hematology (1336) 1336
apoptosis (1311) 1311
rats, wistar (1281) 1281
administration, oral (1258) 1258
cell proliferation - drug effects (1238) 1238
disease models, animal (1216) 1216
receptor, cannabinoid, cb1 - antagonists & inhibitors (1211) 1211
inhibition (1210) 1210
pyridines - pharmacology (1197) 1197
models, molecular (1192) 1192
design (1175) 1175
in vitro techniques (1149) 1149
apoptosis - drug effects (1102) 1102
pyrazoles - metabolism (1090) 1090
cell biology (1080) 1080
cells, cultured (1071) 1071
pyrazoles - pharmacokinetics (1061) 1061
care and treatment (1058) 1058
protein kinase inhibitors - pharmacology (1028) 1028
signal transduction - drug effects (1027) 1027
biological evaluation (1002) 1002
aged, 80 and over (981) 981
mice, inbred c57bl (937) 937
cyclooxygenase inhibitors - pharmacology (934) 934
kinetics (933) 933
enzyme inhibitors - pharmacology (930) 930
in-vitro (929) 929
abridged index medicus (922) 922
catalysis (900) 900
pyridines - therapeutic use (891) 891
sulfonamides - adverse effects (889) 889
organic chemistry (885) 885
rimonabant (879) 879
protein kinase inhibitors - therapeutic use (878) 878
pyridones - therapeutic use (870) 870
potent (850) 850
cells (848) 848
mutation (841) 841
phosphorylation (839) 839
pyrimidines - therapeutic use (836) 836
cell line (830) 830
antineoplastic agents - therapeutic use (815) 815
brain (797) 797
drug design (785) 785
crystallography (784) 784
signal transduction (784) 784
medicine, general & internal (778) 778
endocannabinoids (771) 771
cyclooxygenase 2 (770) 770
sulfonamides - administration & dosage (768) 768
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (41311) 41311
German (745) 745
Japanese (494) 494
Chinese (360) 360
French (293) 293
Italian (264) 264
Russian (171) 171
Spanish (149) 149
Portuguese (137) 137
Polish (79) 79
Czech (53) 53
Norwegian (24) 24
Danish (20) 20
Dutch (20) 20
Hungarian (18) 18
Swedish (16) 16
Romanian (10) 10
Croatian (8) 8
Korean (8) 8
Slovak (7) 7
Turkish (6) 6
Finnish (5) 5
Ukrainian (5) 5
Serbian (3) 3
Arabic (2) 2
Bulgarian (2) 2
Galician (1) 1
Greek (1) 1
Lithuanian (1) 1
Malay (1) 1
Persian (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Drug metabolism and disposition, ISSN 0090-9556, 01/2015, Volume 43, Issue 2, pp. 289 - 297
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 1, pp. 32 - 42
Ibrutinib inhibits Bruton's tyrosine kinase, a component of normal B-cell activation pathways. Ibrutinib produced responses in 71% of patients with refractory... 
MEDICINE, GENERAL & INTERNAL | BRUTONS TYROSINE KINASE | ACTIVATION | RITUXIMAB | B-CELL MALIGNANCIES | PCI-32765 | SURVIVAL SIGNALS | KAPPA-B | INHIBITOR | ANTIGEN RECEPTOR | FLUDARABINE | Recurrence | Pyrazoles - therapeutic use | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Pyrazoles - pharmacokinetics | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Treatment Outcome | Pyrimidines - pharmacology | Remission Induction | Disease-Free Survival | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Chronic lymphocytic leukemia | Care and treatment | Product development | Antineoplastic agents | Tyrosine | Cell proliferation | Pharmacodynamics | Chronic lymphatic leukemia | Cell survival | Leukemia | Diarrhea | Fatigue | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Risk factors | Cell adhesion & migration | Clonal deletion | Lymphocytes B | Respiratory tract diseases | Lymphomas | Pharmacokinetics | Lymphocytosis | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Crizotinib | Treatment outcome | Chemotherapy | Usage | Care and treatment | Lung cancer | Analysis | Dosage and administration | Comparative analysis | Risk factors | Cancer | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 9, pp. 799 - 808
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2010, Volume 107, Issue 29, pp. 13075 - 13080
Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.... 
T lymphocytes | Animal models | Disease models | Gels | B lymphocytes | B cell lymphoma | Arthritis | Mice | Autoimmune diseases | Tumors | X-linked agammaglobulinemia | Lymphoma | COLLAGEN-INDUCED ARTHRITIS | THERAPY | RITUXIMAB | MULTIDISCIPLINARY SCIENCES | lymphoma | DOGS | FAMILY KINASES | BTK | RECEPTOR | DEPLETION | MICE | Arthritis, Experimental - drug therapy | Pyrazoles - therapeutic use | Humans | Benzofurans - administration & dosage | Benzofurans - pharmacology | Autoantibodies - biosynthesis | Pyrimidines - chemistry | Benzofurans - chemistry | Protein Kinase Inhibitors - chemistry | Pyrazoles - chemistry | Lymphoma, B-Cell - enzymology | Autoimmune Diseases - drug therapy | Disease Models, Animal | Lymphoma, B-Cell - drug therapy | Pyrazoles - pharmacology | B-Lymphocytes - enzymology | Benzofurans - therapeutic use | Autoimmune Diseases - enzymology | Administration, Oral | Pyrimidines - administration & dosage | Treatment Outcome | Pyrimidines - pharmacology | Receptors, Antigen, B-Cell - immunology | B-Lymphocytes - drug effects | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Animals | B-Lymphocytes - immunology | Signal Transduction - drug effects | Lymphocyte Activation - drug effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Dogs | Protein Kinase Inhibitors - pharmacology | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Cell receptors | Models | Lymphomas | Research | Properties | Biological Sciences
Journal Article
Journal Article